News | February 17, 2024
Internal restructuring of foreign subsidiaries at Bliss GVS Pharma
The restructuring aims to create synergies across the business and strengthen capital structure
The restructuring aims to create synergies across the business and strengthen capital structure
The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024
Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
The company's SaaS solutions are tailored to enhance accessibility, efficiency, and patient-centricity in healthcare operations
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
The CDCCs are strategically positioned in regions identified as high-impact areas
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
Subscribe To Our Newsletter & Stay Updated
